Vasculitis & polymyalgia rheumatica
Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups
Authors' conclusion
This first genome-wide association study stratified by GCA-specific manifestations deepens our understanding of the genetic basis underlying GCA clinical heterogeneity.
Study context
- Population
- Patients with giant cell arteritis (GCA) and controls with genome-wide genotype data
- Participants
- 3,498 vs 15,550
- Comparison
- Patients with GCA with vs without each clinical manifestation; each subgroup vs controls
- GCAn = 3,498
- Controlsn = 15,550reference
- Outcome
- Genetic risk factors associated with GCA clinical manifestations
Methodological detailsstratified by GCA-specific manifestations, logistic regression, latent class analysis
- Stratified by GCA-specific manifestations
- Logistic regression
- Latent class analysis
Main finding
As reported in the abstract
Genetic associations with GCA clinical manifestations
Human leukocyte antigen (HLA) variants specifically associated with different clinical features
7
Non-HLA associations across 6 clinical manifestations
7
Further findings
Latent class analysis (LCA) classes of GCA clinical predisposition
- Classes: cranial-predominant, mixed, extracranial, ischaemic/occlusive (high-risk subgroup for severe ischaemic and ocular complications)
- 4
Original publication
Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups. Ann Rheum Dis. Published 3 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →